HR Execs on the Move

UniQure

www.uniqure.com

 
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.uniqure.com
  • 113 Hartwell Avenue
    Lexington, MA USA 02421
  • Phone: 339.970.7000

Executives

Name Title Contact Details
Ricardo Dolmetsch
President of Research and Development Profile
Roger Evans
Senior Director, R&D QA Profile
Jamie Brady
Chief Human Resources Officer Profile
Erin Boyer
Chief People and Culture Officer Profile
Carla Poulson
Chief People and Culture Officer Profile

Similar Companies

Medsource RX

Medsource RX is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vireo Health

Vireo Health, Inc. a physician-led multi-state medical cannabis company, is committed to safely alleviating pain by providing patients with best-in-class cannabis products and compassionate care.

Mixlab

Mixlab is a modern veterinary pharmacy that specializes in pharmaceutical manufacturing and compounding for veterinary use.

Proacta

Proacta Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.